n e w s Improving an Immunotoxin

First Page		Document Content
Date: 2012-02-01 13:39:44 Medicine Immunotoxin Monoclonal antibodies Ira Pastan Fusion protein Antibody Immunogenicity Antigen Anti-CD22 immunotoxin Immune system Biology Immunology		n e w s Improving an Immunotoxin Add to Reading List Source URL: home.ccr.cancer.gov Download Document from Source Website File Size: 62,73 KB Share Document on Facebook

	November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent DocID: 1aF51 - View Document
	Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate cancer therapy. It is highly expresse DocID: 1afSk - View Document
	Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate DocID: GXPp - View Document
	A Better Immunotoxin Through inspired engineering, proteins that enter and kill cancer cells are finding their place among cancer treatments. (Photo: R. Baer) DocID: Gf5A - View Document
	OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In DocID: FMnR - View Document